{
  "cik": 2044725,
  "cik_padded": "0002044725",
  "entityName": "Evommune, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-093932",
      "filed": "2026-03-05",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 235000.0,
        "cash": 44063000.0,
        "eps_diluted": -11.22,
        "free_cash_flow": -76676000.0,
        "net_income": -68870000.0,
        "operating_cash_flow": -76441000.0,
        "operating_income": -81071000.0,
        "revenue": 13000000.0,
        "stockholders_equity": 205566000.0,
        "total_assets": 224946000.0,
        "total_liabilities": 19380000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.09427629082630395,
        "revenue_growth_yoy": 0.8571428571428571,
        "roa_avg2y": -0.4576064531347072,
        "roa_period_end": -0.3061623678571746,
        "roe_avg2y": -2.2459195486637644,
        "roe_period_end": -0.3350262202893475
      }
    },
    {
      "accn": "0001193125-26-093932",
      "filed": "2026-03-05",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 88000.0,
        "cash": 16255000.0,
        "eps_diluted": -45.29,
        "free_cash_flow": -58283000.0,
        "net_income": -66808000.0,
        "operating_cash_flow": -58195000.0,
        "operating_income": -70013000.0,
        "revenue": 7000000.0,
        "stockholders_equity": -144237000.0,
        "total_assets": 76055000.0,
        "total_liabilities": 28516000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.8784169351127473,
        "roe_avg2y": 0.6020067492374443
      }
    },
    {
      "accn": "0001193125-26-093932",
      "filed": "2026-03-05",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -77714000.0
      },
      "period_end": "2023-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-093932",
    "filed": "2026-03-05",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002044725.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0002044725.json"
  },
  "ticker": "EVMN"
}